JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.3
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 14, Issue 4 (2022)
Iran J War Public Health 2022, 14(4): 409-414 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2022/08/1 | Accepted: 2022/11/21 | Published: 2022/11/29
Received: 2022/08/1 | Accepted: 2022/11/21 | Published: 2022/11/29
How to cite this article
AL-Husaini F, Hywar F, Elias N, Falih I. Evaluation of Chemerin in Diabetic Type 2 Patients with Metabolic Syndrome in both Gender. Iran J War Public Health 2022; 14 (4) :409-414
URL: http://ijwph.ir/article-1-1258-en.html
URL: http://ijwph.ir/article-1-1258-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Dentistry, Al- Manara College for Medical Sciences, University of Misan, Maysan, Iraq
2- Department of Biochemistry, Al-Zahraa College of Medicine, University of Basrah, Basra, Iraq
3- College of Health and Medical Techniquse, Middle Technical University, Baghdad, Iraq
4- Department of Chemistry, College of Science, University of Misan, Maysan, Iraq
2- Department of Biochemistry, Al-Zahraa College of Medicine, University of Basrah, Basra, Iraq
3- College of Health and Medical Techniquse, Middle Technical University, Baghdad, Iraq
4- Department of Chemistry, College of Science, University of Misan, Maysan, Iraq
Abstract (523 Views)
Aims: Chemerin abnormal level represents a risk indicator of visceral fat increase. It has a role in the incidence of inflammation, insulin resistance, metabolic syndrome, obesity, and diabetes. This study aimed to evaluate Chemerin level in diabetic type 2 patients with metabolic syndrome in both Genders.
Materials & Methods: This study was carried out on the patients referred to the Al-Yarmouk Teaching Hospital in 2021-2022. 88 participants were selected by random sampling method and were divided into two groups including T2DM patients with metabolic syndrome in the experience group (n=55) compared with healthy subjects in the control group (n=38). Triacylglycerol (TG), High-Density Lipoprotein-Cholesterol (HDL-c), Obesity (BMI), serum Chemerin, Hypertension (SBP), age, Fasting Blood Glucose (FBG), and Glycated Haemoglobin (HbA1C) were measured in the two studied groups. Data were analyzed using T-test through SPSS 21 Software.
Findings: A significant difference was observed between the levels of BMI, SBP, FBG, TG, HDL-c, Chemerin weight, DBP, and HbA1c in the studied groups (p=0.05). The rate of WC and HDL-c was higher in the females than in males in the experience group. While, there was a significant increase in the rates of SBP, FBG, TG, and Chemerin in males than females. A positive correlation coefficient was observed between age, SBP, WC, BMI, FBG, TG, and HbA1c with Chemerin level in the experience group.
Conclusion: An increase in Chemerin level is associated with a high level of triglycerides during the onset of symptoms of metabolic syndrome, age, and gender, which affect the increase of adipokine.
Materials & Methods: This study was carried out on the patients referred to the Al-Yarmouk Teaching Hospital in 2021-2022. 88 participants were selected by random sampling method and were divided into two groups including T2DM patients with metabolic syndrome in the experience group (n=55) compared with healthy subjects in the control group (n=38). Triacylglycerol (TG), High-Density Lipoprotein-Cholesterol (HDL-c), Obesity (BMI), serum Chemerin, Hypertension (SBP), age, Fasting Blood Glucose (FBG), and Glycated Haemoglobin (HbA1C) were measured in the two studied groups. Data were analyzed using T-test through SPSS 21 Software.
Findings: A significant difference was observed between the levels of BMI, SBP, FBG, TG, HDL-c, Chemerin weight, DBP, and HbA1c in the studied groups (p=0.05). The rate of WC and HDL-c was higher in the females than in males in the experience group. While, there was a significant increase in the rates of SBP, FBG, TG, and Chemerin in males than females. A positive correlation coefficient was observed between age, SBP, WC, BMI, FBG, TG, and HbA1c with Chemerin level in the experience group.
Conclusion: An increase in Chemerin level is associated with a high level of triglycerides during the onset of symptoms of metabolic syndrome, age, and gender, which affect the increase of adipokine.
Keywords:
Metabolic Syndrome [MeSH], Angiogenesis [MeSH], T2DM [MeSH], Aging Process [MeSH], Adipokines [MeSH]
References
1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16. [Link] [DOI:10.1001/jama.288.21.2709]
2. Gathirua-Mwangi WG, Monahan PO, Murage MJ, Zhang J. Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes Control. 2017;28:127-36. [Link] [DOI:10.1007/s10552-016-0843-1]
3. Parker J. Glucose metabolism, energy production and regulation of cellular and whole-body metabolism. J ACNEM. 2020;39(1):1-9 [Link]
4. Félix NDC, Nóbrega MMLD. Síndrome metabólica: análise conceitual no contexto da enfermagem. Revista Latino-Americana de Enfermagem. 2019;27:e3154,2019. [Link] [DOI:10.1590/1518-8345.3008.3154]
5. Aguilar-Salinas CA, Viveros-Ruiz T. Recent advances in managing/understanding the metabolic syndrome. F1000Res. 2019;8:370 [Link] [DOI:10.12688/f1000research.17122.1]
6. Farkhondeh T, Llorens S, Pourbagher-Shahri AM, Ashrafizadeh M, Talebi M, Shakibaei M, et al. An overview of the role of adipokines in cardiometabolic diseases. Molecules. 2020;25(21):5218. [Link] [DOI:10.3390/molecules25215218]
7. Pérez-Pevida B, Díaz-Gutiérrez J, Miras AD, Silva C, Romero S, Salvador J, et al. High body adiposity drives glucose intolerance and increases cardiovascular risk in normoglycemic subjects. Obesity (Silver Spring). 2018;26(4):672-82. [Link] [DOI:10.1002/oby.22147]
8. Zhou Z, Chen H, Ju H, Sun M. Circulating chemerin levels and gestational diabetes mellitus: A systematic review and meta-analysis. Lipids Health Dis. 2018;17(169):17. [Link] [DOI:10.1186/s12944-018-0826-1]
9. Kouvari M, Panagiotakos DB, Yannakoulia M, Georgousopoulou E, Critselis E, Chrysohoou C, et al. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: The ATTICA cohort study. Metabolism. 2019;93:18-24. [Link] [DOI:10.1016/j.metabol.2019.01.003]
10. Francisco V, Ruiz-Fernández C, Pino J, Mera A, González-Gay MA, Gómez R, et al. Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases. Biochem Pharmacol. 2019;165:196-206. [Link] [DOI:10.1016/j.bcp.2019.03.030]
11. Zylla S, Pietzner M, Kuhn JP, Volzke H, Dorr M, Nauck M, et al. Serum chemerin is associated with inflammatory and metabolic parameters-results of a population-based study. Obesity (Silver Spring). 2017;25:468-75. [Link] [DOI:10.1002/oby.21735]
12. Bobbert T, Schwarz F, Fischer-Rosinsky A, Maurer L, Mohlig M, Pfeiffer AF, et al. Chemerin and prediction of diabetes mellitus type 2. Clinic Endocr. 2015;82(6):838-43. [Link] [DOI:10.1111/cen.12707]
13. Leiherer A, Muendlein A, Kinz E, Vonbank A, Rein P, Fraunberger P, et al. High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events- insights from phenotype and genotype characterization. Vasc Pharmacol. 2016;77:60-8 [Link] [DOI:10.1016/j.vph.2015.08.010]
14. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148(10):4687-94. [Link] [DOI:10.1210/en.2007-0175]
15. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. A novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282(38):28175-88. [Link] [DOI:10.1074/jbc.M700793200]
16. Ernst MC, Sinal CJ. Chemerin: At the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010;21(11):660-7. [Link] [DOI:10.1016/j.tem.2010.08.001]
17. Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev. 2013;14(3):245-62. [Link] [DOI:10.1111/obr.12009]
18. Fatima SS, Rehman R, Baig M, Khan TA. New roles of the multidimensional adipokine: Chemerin. Peptides. 2014;62:15-20. [Link] [DOI:10.1016/j.peptides.2014.09.019]
19. Li Y, Shi B, Li S. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: A meta-analysis. PLoS One. 2014;9(12):e113915. [Link] [DOI:10.1371/journal.pone.0113915]
20. Buechler C, Feder S, Haberl E, Aslanidis C. Chemerin isoforms and activity in obesity. Int J Mol Sci. 2019;20(5):1128-2019. [Link] [DOI:10.3390/ijms20051128]
21. Biadgo B, Melak T, Ambachew S, Baynes HW, Limenih MA, Jaleta KN, et al. The prevalence of metabolic syndrome and its components among type 2 diabetes mellitus patients at a tertiary hospital, Northwest Ethiopia. Ethiop J Health Sci. 2018;28(5):645-54. [Link] [DOI:10.4314/ejhs.v28i5.16]
22. Kumari R, Kumar S, Kant R. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr. 2019;13(4):2409-17. [Link] [DOI:10.1016/j.dsx.2019.06.005]
23. Nappo A, Gonzalez-Gil EM, Ahrens W, Bammann K, Michels N, Moreno LA. Analysis of the association of leptin and adiponectin concentrations with metabolic syndrome in children: Results from the IDEFICS study. Nutri Metab Cardiovasc Dis. 2017;27(6):543-51. [Link] [DOI:10.1016/j.numecd.2017.04.003]
24. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364-73. [Link] [DOI:10.1016/j.tcm.2015.10.004]
25. Zimmet P, Alberti KGM, Kaufman F, Tajima N, Silink M. Arslanian S, et al. The metabolic syndrome in children and adolescents-an IDF consensus report. Pediatr Diabetes. 2007;8(5):299-306. [Link] [DOI:10.1111/j.1399-5448.2007.00271.x]
26. World Health Organization. International society of hypertension guidelines for the management of hypertension. guidelines subcommitte. J Hypertens. 1999;17(2):151-83. [Link] [DOI:10.1097/00004872-199917020-00001]
27. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: Age- and sex-specific prediction formulas. Br J Nutr. 2007;65(2):105-14. [Link] [DOI:10.1079/BJN19910073]
28. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al. IFCC Working Group on HbA1c Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: A method- comparison study. Clin Chem. 2004;50(1):166-74. [Link] [DOI:10.1373/clinchem.2003.024802]
29. Fossati P, Prencipe L. Serum triglycerides determined calorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28(10):2077-80. [Link] [DOI:10.1093/clinchem/28.10.2077]
30. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11(6):583-95. [Link] [DOI:10.1016/S0022-2275(20)42943-8]
31. Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol. 2010;185(6):3728-39. [Link] [DOI:10.4049/jimmunol.0902154]
32. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97 [Link] [DOI:10.1038/nri2921]
33. Lambernd S, Taube A, Schober A, Platzbecker B, Görgens SW, et al. Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signaling pathways. Diabetologia. 2012;55(4):1128-39. [Link] [DOI:10.1007/s00125-012-2454-z]
34. Perumalsamy S, Aqilah Mohd Zin NA, Widodo RT, Wan Ahmad WA, Vethakkan SRDB, Huri HZ. Chemokine like receptor-1 (CMKLR-1) receptor: A potential therapeutic target in management of chemerin induced type 2 diabetes mellitus and cancer. Curr Pharm Des. 2017;23(25):3689-98. [Link] [DOI:10.2174/1381612823666170616081256]
35. Alowfi A, Binladen S, Irqsous S, Khashoggi A, Khan MA, Calacattawi R. Metabolic syndrome: prevalence and risk factors among adolescent female intermediate and secondary students in Saudi Arabia. Int J Environ Res Public Health. 2021;18(4):2142. [Link] [DOI:10.3390/ijerph18042142]
36. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. [Link] [DOI:10.1093/clinchem/18.6.499]
37. Tachebele B, Abebe M, Addis Z, Mesfin N. Metabolic syndrome among hypertensive patients at University of Gondar Hospital, North West Ethiopia: A cross sectional study. BMC Cardiovasc Dis. 2014;14(177). [Link] [DOI:10.1186/1471-2261-14-177]
38. Okafor CI. The metabolic syndrome in Africa: Current trends. Indian J Endocrinol Metab. 2012;16(1):56-66. [Link] [DOI:10.4103/2230-8210.91191]
39. Thomas MM, Zaki ME, Youness E, Hamed K, Khedr AA, Abd PM, et al. Measurement of serum chemerin, oxidized LDL, and vitamin D levels in Prader-Willi syndrome: A cross-sectional study in pediatric egyptian patients. J Child Sci. 2020;10(1):e187-95. [Link] [DOI:10.1055/s-0040-1718896]
40. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine. 2006;29(1):81-90. [Link] [DOI:10.1385/ENDO:29:1:81]
41. Panagiotakos BP, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis. 2005;183(2):308-15. [Link] [DOI:10.1016/j.atherosclerosis.2005.03.010]
42. Zaki ME, Youness E, Gadelhak M. DNA damage and neutrophil elastase in children with Prader-Willi syndrome. Biomed Pharmacol J. 2019;12(4):1967-74. [Link] [DOI:10.13005/bpj/1828]
43. Alfadda AA, Sallam RM, Chishti MA, Moustafa AS, Fatma S, Alomaim WS, Jo H. Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: Adipose depot specificity and gender dimorphism. Mol Cells. 2012;33(6):591-6. [Link] [DOI:10.1007/s10059-012-0012-7]
44. Helfer G, Wu QF. Chemerin: A multifaceted adipokine involved in metabolic disorders. J Endocrinol. 2018;238(2):79-94. [Link] [DOI:10.1530/JOE-18-0174]
45. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009;94(8):3085-8. [Link] [DOI:10.1210/jc.2008-1833]
46. Tahir NT, Israa Falih Q, Khudhair AL-Husaini F, Sali Abed Z. Study the effect of chemerin level in type ii diabetic patients with and without retinopathy. Syst Rev Pharm. 2020;11(1):1-6. [Link]
47. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig. 2015;21(1):57-74. [Link] [DOI:10.1515/hmbci-2014-0037]
48. Coimbra S, Brandão Proença J, Santos-Silva A, Neuparth MJ. Adiponectin, leptin, and chemerin in elderly patients with type 2 diabetes mellitus: A close linkage with obesity and length of the disease. BioMed Res Int. 2014;2014:701915. [Link] [DOI:10.1155/2014/701915]
49. Sell H, Divoux A, Poitou C. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010;95(6):2892-6. [Link] [DOI:10.1210/jc.2009-2374]
50. Lehrke M, Becker A, Greif M. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009;161(2):339-44. [Link] [DOI:10.1530/EJE-09-0380]